Skip to content

Multimodality Neuromonitoring in XLIF

Multimodality Neuromonitoring In eXtreme Lateral Interbody Fusion (XLIF®)

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01499680
Acronym
NV in XLIF®
Enrollment
323
Registered
2011-12-26
Start date
2011-10-31
Completion date
2014-06-30
Last updated
2025-12-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Degeneration of Lumbar Intervertebral Disc

Keywords

Degenerative Lumbar Conditions

Brief summary

This is a prospective, non-randomized multi-center study to evaluate intraoperative neuromonitoring results in subjects who undergo eXtreme Lateral Interbody Fusion (XLIF) surgery at any number of levels inclusive of L4-5.

Detailed description

Subjects will present with degenerative conditions in the lumbar spine that are amenable to surgical treatment and will be screened prior to study enrollment. Subjects will undergo neuromonitoring during the XLIF operation, as per standard care. They will then be re-evaluated immediately after surgery and at the first standard postoperative follow-up visit (6 weeks) to assess for presence of new neural deficit. If a new neural deficit is identified, the patient will be followed per the Investigator's standard follow-up schedule until symptoms have resolved (or are deemed permanent). A total of 300 subjects will be enrolled in this study from multiple centers. The subjects will have degenerative conditions of the lumbar spine with planned treatment including XLIF surgery. The following eligibility criteria are designed to identify existing clinic patients for whom study under this protocol is considered appropriate. All subjects must meet the inclusion/exclusion criteria below in order to be considered for enrollment.

Interventions

None listed

Sponsors

NuVasive
Lead SponsorINDUSTRY

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Persistent back and/or leg pain unresponsive to conservative treatment for at least six (6) months, unless surgical treatment is clinically indicated earlier * Indicated for extreme lateral interbody fusion at any number of levels inclusive of L4-5 * At least 18 years of age at the date of written informed consent * Able to undergo surgery based on physical exam, medical history and surgeon judgment * Willing and able to return for post-treatment exams according to the follow-up called for in the protocol * Signed and dated informed consent form

Exclusion criteria

* Patient has a mental or physical condition that would limit the ability to comply with study requirements * Patient is a prisoner * Patient is involved in active litigation relating to the spine (worker's compensation claim is allowed if it is not contested) * Patient has an underlying neurological disease or neurological deficit that is not associated with the condition for which he/she is seeking surgical intervention (e.g., diabetic peripheral neuropathy) * Patient is participating in another clinical study that would confound study data

Design outcomes

Primary

MeasureTime frameDescription
The sensitivity and specificity of EMG and SSEP (if available) testing in identifying neural injury.8 weeksFor evaluation of the primary endpoint and additional assessments, descriptive statistics including mean, standard deviation, minimum, median, and maximum for continuous variables and frequency distribution for categorical variables will be provided, as well as tabular listings. All complications will be itemized including incidence, duration, and relationship to devices used and/or procedures performed.

Countries

Puerto Rico, Switzerland, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026